Bayesian Capital Management’s Core Laboratories CLB Stock Holding History

Bayesian Capital Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,073	Closed	-$146K	–	553
2020 Q1	$146K	Buy	+14,073	New	+$394K	0.03%	626
2019 Q3	–	Sell	-4,600	Closed	-$240K	–	534
2019 Q2	$240K	Buy	+4,600	New	+$270K	0.05%	408
2018 Q1	–	Sell	-5,100	Closed	-$559K	–	609
2017 Q4	$559K	Buy	+5,100	New	+$509K	0.11%	292

Other funds holding CLB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AKO Capital London, United Kingdom $4.29B AUM 4.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bayesian Capital Management's CLB Position: Q2 2020 in Review

Bayesian Capital Management sold out of Core Laboratories (CLB) in Q2 2020, closing a stake of 14,073 shares — an estimated $146K sold.

Bayesian Capital Management first reported a position in CLB in Q4 2017 and held it in 3 quarters. The position peaked at $559K in Q4 2017. 197 funds tracked by Wall St. Rank hold CLB as of Q2 2020.

Bayesian Capital Management reported no remaining Core Laboratories position as of Q2 2020 after selling out during the quarter.
Bayesian Capital Management sold 14,073 Core Laboratories shares in Q2 2020, an estimated $146K.
Bayesian Capital Management first reported a position in Core Laboratories in Q4 2017 and held it in 3 quarters.
Bayesian Capital Management's Core Laboratories position peaked at $559K in Q4 2017.
197 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2020.

Based on Bayesian Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.